Bone filler material cleared in the US:
This article was originally published in Clinica
Executive Summary
Interpore Cross International has received US clearance to market a resorbable filler material for voids in bone. The Pro Osteon 500R material, a resorbable version of the Irvine, California-based company's best-selling synthetic bone graft, is cleared for use in voids in the skeletal system, such as the spine, pelvis and extremities. These voids are caused by cancer, fractures and the harvesting of bone for use in reconstructive surgery.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.
Changes To EU Pharma Reform: More Questions Than Answers?
In the first of a series of articles on the future direction of the EU pharmaceutical reform proposals, the Pink Sheet looks at the new uncertainties created for the drug industry after the European Parliament voted through a series of amendments in the area of regulatory data protection.